These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 19020658)
1. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. Bartolazzi A; D'Alessandria C; Parisella MG; Signore A; Del Prete F; Lavra L; Braesch-Andersen S; Massari R; Trotta C; Soluri A; Sciacchitano S; Scopinaro F PLoS One; 2008; 3(11):e3768. PubMed ID: 19020658 [TBL] [Abstract][Full Text] [Related]
2. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive Peplau E; De Rose F; Reder S; Mittelhäuser M; Scafetta G; Schwaiger M; Weber WA; Bartolazzi A; Skerra A; D'Alessandria C Thyroid; 2020 Sep; 30(9):1314-1326. PubMed ID: 32200708 [No Abstract] [Full Text] [Related]
4. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
5. Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer. De Rose F; Braeuer M; Braesch-Andersen S; Otto AM; Steiger K; Reder S; Mall S; Nekolla S; Schwaiger M; Weber WA; Bartolazzi A; D'Alessandria C J Nucl Med; 2019 Jun; 60(6):770-776. PubMed ID: 30361380 [TBL] [Abstract][Full Text] [Related]
6. Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules. Sciacchitano S; Lavra L; Ulivieri A; Magi F; Porcelli T; Amendola S; De Francesco GP; Bellotti C; Trovato MC; Salehi LB; Bartolazzi A Endocrine; 2016 Oct; 54(1):139-147. PubMed ID: 26475496 [TBL] [Abstract][Full Text] [Related]
7. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Aron M; Kapila K; Verma K Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3. D'Alessandria C; Braesch-Andersen S; Bejo K; Reder S; Blechert B; Schwaiger M; Bartolazzi A Cancer Res; 2016 Jun; 76(12):3583-92. PubMed ID: 27216181 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967 [TBL] [Abstract][Full Text] [Related]
11. Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules. Hooft L; van der Veldt AA; Hoekstra OS; Boers M; Molthoff CF; van Diest PJ Clin Endocrinol (Oxf); 2008 Feb; 68(2):252-7. PubMed ID: 17868400 [TBL] [Abstract][Full Text] [Related]
12. [Significance of galectin-3 and CD44v6 expression in differential diagnosis of thyroid nodules]. Wang LH; Zhao YJ; Wang XY; Yuan P; Xu WQ; Xiao JC; Xu JP; Luo BR Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):547-50. PubMed ID: 16438854 [TBL] [Abstract][Full Text] [Related]
14. Galectin-3 and CD117 immunocytochemistry in the diagnosis of indeterminate thyroid lesions: A pilot study. Dixit S; Diwaker P; Wadhwa N; Arora VK Diagn Cytopathol; 2021 Oct; 49(10):1129-1137. PubMed ID: 34297482 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. Bartolazzi A; Sciacchitano S; D'Alessandria C Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393868 [TBL] [Abstract][Full Text] [Related]
16. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules. Han RL; Wang J; Zhang FJ; Zhao N; Gao BL Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909 [TBL] [Abstract][Full Text] [Related]
17. Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Bartolazzi A; Bellotti C; Sciacchitano S Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):2-7. PubMed ID: 21691201 [TBL] [Abstract][Full Text] [Related]
18. Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer. Li J; Vasilyeva E; Wiseman SM Expert Rev Anticancer Ther; 2019 Dec; 19(12):1017-1027. PubMed ID: 31757172 [No Abstract] [Full Text] [Related]
19. (99m)Tc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology. Campennì A; Giovanella L; Siracusa M; Alibrandi A; Pignata SA; Giovinazzo S; Trimarchi F; Ruggeri RM; Baldari S Thyroid; 2016 Aug; 26(8):1101-9. PubMed ID: 27266385 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]